SLSのチャート
SLSの企業情報
| symbol | SLS |
|---|---|
| 会社名 | SELLAS Life Sciences Group Inc （ガリ―ナ・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アールエックスアイ・ファーマシューティカルズ（RXi Pharmaceuticals Corporation）はリボ核酸（RNA）干渉（RNAi）を標的とした技術と免疫療法技術を利用して、アンメットメディカルニーズに対処する治療法の発見・開発・商用化に従事するバイオ企業。同社は種々の癌の治療のために、主要な製品候補「NeuVaxtm」を含むペプチドベースの免疫療法製品を活用する癌の治療法、及び標的となる疾患関連遺伝子を発現、或いは発現抑制する自然発生的な細胞メカニズムのRNA干渉（RNAi）に基づいた治療法を追求する。同社の主要な製品は「Herceptin」に不適格の初・中期HER２陽性乳癌患者において乳癌の再発を減少させるペプチドベースの免疫療法「NeuVax」。同社のRNAi製品「RXI-109」は結合組織成長因子を標的とする皮膚抗瘢痕治療法。平成23年4月13日、同社は民間のバイオ企業Apthera Inc. (Apthera)を買収した。 ガリ―ナ・バイオファ―マは、米国のバイオ医薬品企業。癌性疼痛の持続的疼痛管理時の急激な痛み（突出痛）に対して、舌下投与による有効成分フェンタニルの速やかな吸収と鎮痛効果を主薬効とする治療剤アブストラルや、原発性癌の免疫療法の癌の再発の予防のためにNeuVaxを開発。また、婦人科癌、卵巣癌および子宮内膜腺癌で臨床試験の段階の製品もある。 SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, NPS, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care. |
| 本社所在地 | 15 West 38th Street 10th Floor New York NY 10018 USA |
| 代表者氏名 | Angelos M. Stergiou Angelos M. Stergiou |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 917-438-4353 |
| 設立年月日 | 38808 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 11人 |
| url | www.sellaslife.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sls |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.27600 |
| 終値（lastsale） | 1.2864 |
| 時価総額（marketcap） | 25178151.4752 |
| 時価総額 | 時価総額（百万ドル） 30.53321 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 36.96321 |
| 当期純利益 | 当期純利益（百万ドル） -33.53800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sellas Life Sciences Group Inc revenues was not reported. Net loss applicable to common stockholders increased 76% to $18.5M. Higher net loss reflects General and administrative - Balancing v increase from $3.8M to $8.7M (expense) Change in fair value of the contingent p increase from $0K to $3.9M (expense) Gain/Loss on Derivatives - Hedging increase from $0K to $727K (expense). |
SLSのテクニカル分析
SLSのニュース
Was anything positive for SELLAS Life Sciences Group Inc. (SLS) stock last session? 2022/11/24 12:40:00 US Post News
The share price of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) rose to $2.46 per share on Wednesday from $2.42. While SELLAS Life Sciences Group Inc. has overperformed by 1.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SLS fell by -63.93%, with highs and lows ranging […]
US stocks closed lower, Dow Jones down 0.63% 2022/11/15 02:40:43 InstaForex
At the close of the New York Stock Exchange, the Dow Jones fell 0.63%, the S&P 500 fell 0.89%, and the NASDAQ Composite index fell 1.12%. Merck & Company Inc was the top gainer among the components of the Dow Jones index today, up 2.39 points or 2.44% to close at 100.35. Quotes of Johnson & Johnson rose by 2.66 points (1.57%), ending trading at 171.91. Visa Inc Class A rose 1.86 points or 0.91% to close at 206.86. The least gainers were Walmart Inc, which shed 4.19 points or 2.94% to end the session at 138.39. Home Depot Inc was up 2.55% or 8.02 points to close at 306.92 while Dow Inc was down 2.24% or 1.19 points to close at 51. 95. Leading gainers among the components of the S&P 500 in today''s trading were CF Industries Holdings Inc, which rose 5.21% to hit 107.76, PENN Entertainment Inc, which gained 4.59% to close at 37.63. as well as Moderna Inc, which rose 4.57% to close the session at 179.03. The least gainers were Hasbro Inc, which shed 9.86% to close at 57.16. Shares of Bath & Body Works Inc. lost 8.17% and ended the session at 33.06.
SELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated 2022/11/14 18:25:18 Benzinga
SELLAS Life Sciences Group Inc (NASDAQ: SLS ) announced updates relating to its ongoing Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients). A review of preliminary data suggests that the median overall survival (OS) in the pooled study population is likely considerably longer, by approximately two-fold, than initially anticipated and upon which the statistical analysis plan was based. Related:
SELLAS Craters After Postponing Cancer Drug Milestone 2022/11/14 16:21:33 TipRanks
Shares of SELLAS Life Sciences Group (NASDAQ: SLS) were in a downward spiral on Monday morning as the late-stage clinical biopharmaceutical company announced a business update. SELLAS announced that it was postponing the interim analysis of its Phase 3 registrational clinical trial for its lead asset galinpepimut-S (GPS) to late next year or early 2024 from its earlier timeline of early next year. GPS is the company''s novel therapy used in the treatment of patients with acute myeloid leukemia (AML).
Opiant, Ardelyx top healthcare gainers; Satsuma, Sellas lead losers'' pack 2022/11/14 15:00:21 Seeking Alpha
Opiant Pharmaceuticals OPNT +113%. Ardelyx (ARDX) +40%. Satsuma Pharmaceuticals STSA -81%. Sellas Life Sciences SLS -37%.
Thinking about buying stock in Indonesia Energy, Kaival Brands, AT&T, Sellas Life Sciences, or Liberty Energy? 2022/10/20 13:31:00 Benzinga
NEW YORK , Oct. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, KAVL, T, SLS, and LBRT. … Full story available on Benzinga.com
Sellas Life Sciences Group (SLS) Investor Presentation - Slideshow (NASDAQ:SLS) 2022/09/30 08:45:14 Seeking Alpha
The following slide deck was published by SELLAS Life Sciences Group, Inc.
NASA to Discuss Status of Next Artemis I Moon Mission Launch Attempt 2022/09/07 21:51:00 Kwhen Finance
SELLAS Life Sciences'' Announces Election of Katherine Bach Kalin to its Board of Directors 2022/08/16 12:30:00 Benzinga
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) ("SELLAS'''' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the election of Katherine Bach Kalin to its Board of Directors. "We are delighted to welcome someone with the breadth and depth of industry experience as Katherine has to join our Board of Directors," stated Jane Wasman, Chair of the Board of SELLAS. "Having spent her career working in strategy, business development, sales and marketing, and finance within the life sciences and healthcare industries, Katherine will be a valuable addition to the SELLAS team as the Company continues to evolve and grow," said Ms. Wasman. Ms. Kalin''s healthcare industry experience spans pharmaceuticals, diagnostics, medical devices and digital health. She currently serves as a non-executive director on the boards of Genfit S.A., a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm, where she sits on the Audit and Finance Committees, and FemHealth Ventures, a venture capital firm that seeks to invest in women''s health.
SELLAS Life Sciences Group PT Lowered to $8 at Ladenburg Thalmann 2022/08/15 10:46:01 Investing.com
https://www.investing.com/news/pro/sellas-life-sciences-group-pt-lowered-to-8-at-ladenburg-thalmann-432SI-2872395
Sellas Life Sciences Group (SLS) Investor Presentation - Slideshow (NASDAQ:SLS) 2022/09/30 08:45:14 Seeking Alpha
The following slide deck was published by SELLAS Life Sciences Group, Inc.
NASA to Discuss Status of Next Artemis I Moon Mission Launch Attempt 2022/09/07 21:51:00 Kwhen Finance
SELLAS Life Sciences'' Announces Election of Katherine Bach Kalin to its Board of Directors 2022/08/16 12:30:00 Benzinga
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) ("SELLAS'''' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the election of Katherine Bach Kalin to its Board of Directors. "We are delighted to welcome someone with the breadth and depth of industry experience as Katherine has to join our Board of Directors," stated Jane Wasman, Chair of the Board of SELLAS. "Having spent her career working in strategy, business development, sales and marketing, and finance within the life sciences and healthcare industries, Katherine will be a valuable addition to the SELLAS team as the Company continues to evolve and grow," said Ms. Wasman. Ms. Kalin''s healthcare industry experience spans pharmaceuticals, diagnostics, medical devices and digital health. She currently serves as a non-executive director on the boards of Genfit S.A., a French, public biopharmaceutical company, where she serves on the Strategy and Alliances Committee, and two private companies, Brown Advisory LLC, an independent investment and strategic advisory firm, where she sits on the Audit and Finance Committees, and FemHealth Ventures, a venture capital firm that seeks to invest in women''s health.